Zydus gets USFDA nod for schizophrenia drug
New Delhi: Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market Clozapine tablets, used in the treatment of severe schizophrenia.
The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 25 mg, 50 mg, 100 mg and 200 mg, Zydus Cadila said in a BSE filing.
The drug will be produced at the group's formulations manufacturing facility at SEZ, Ahmedabad.
The Zydus group has more than 175 approvals and so far filed over 310 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.
Zydus Pharmaceuticals Inc is a wholly-owned subsidiary of Cadila Healthcare Ltd.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd